Senti Bio Showcases Phase 1 Logic-Gated SENTI-202 CAR-NK Therapy with FDA Orphan & RMAT Designations
Senti Bio presented its proprietary Gene Circuit platform and Logic-Gated SENTI-202 CAR-NK therapy at a virtual Cell & Gene Live event on February 19. SENTI-202, in a Phase 1 trial for relapsed/refractory AML and MDS, uses OR and NOT CAR gates plus IL-15 and holds FDA Orphan Drug and RMAT designations.
1. Event Participation
On February 19, Senti Bio participated in a virtual Cell & Gene Live event, sharing insights on emerging technologies in cell therapy development. The company highlighted its approach to enhancing precision and control in engineered cell therapies through synthetic biology.
2. Gene Circuit Platform Overview
Senti Bio’s proprietary Gene Circuit platform integrates synthetic logic gates into cell therapies to increase specificity, control activity post-administration, and reduce off-target effects. This technology aims to refine therapeutic windows and improve safety profiles for next-generation treatments.
3. SENTI-202 Candidate Details
SENTI-202 is an off-the-shelf CAR-NK product candidate that features an OR gate targeting CD33 and FLT3 to eliminate leukemic cells, a NOT gate recognizing EMCN to protect healthy stem cells, and calibrated-release IL-15 to boost cell persistence and activity.
4. Regulatory Designations and Trial Status
SENTI-202 is enrolling adult patients with relapsed/refractory CD33 and/or FLT3-expressing hematologic malignancies in a Phase 1 trial. The candidate has received FDA Orphan Drug and Regenerative Medicine Advanced Therapy designations, potentially expediting its development path.